Does the media refer more to REPL or RCUS?

In the previous week, Arcus Biosciences had 4 more articles in the media than Replimune Group. MarketBeat recorded 9 mentions for Arcus Biosciences and 5 mentions for Replimune Group. Arcus Biosciences' average media sentiment score of 1.15 beat Replimune Group's score of 0.88 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer REPL or OGN?

In the previous week, Replimune Group had 1 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Replimune Group and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Replimune Group's score of 0.88 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, REPL or ALMS?

Alumis has higher revenue and earnings than Replimune Group. Alumis is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A Alumis $24.05M 148.96 -$243.32M -$1.98 N/A

Is REPL or ALMS more profitable?

Replimune Group has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Alumis -2,825.70% -88.79% -70.72%

Does the media prefer REPL or ALMS?

In the previous week, Alumis had 1 more articles in the media than Replimune Group. MarketBeat recorded 6 mentions for Alumis and 5 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.88 beat Alumis' score of 0.44 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to REPL or ARQT?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Replimune Group. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 5 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.88 beat Arcutis Biotherapeutics' score of 0.68 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer REPL or GMTX?

Replimune Group presently has a consensus price target of $8.13, indicating a potential downside of 18.26%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 2 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, REPL or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is REPL or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Gemini Therapeutics N/A -38.78% -35.88%

Does the media refer more to REPL or GMTX?

In the previous week, Replimune Group had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for Gemini Therapeutics. Replimune Group's average media sentiment score of 0.88 beat Gemini Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Replimune Group (REPL) Competitors

$9.94 -1.05 (-9.55%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.90 -0.04 (-0.40%)

As of 08:28 AM Eastern

Compare

REPL vs. RCUS, OGN, ALMS, ARQT, and GMTX

Should you buy Replimune Group stock or one of its competitors? MarketBeat compares Replimune Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Replimune Group include Arcus Biosciences (RCUS), Organon & Co. (OGN), Alumis (ALMS), Arcutis Biotherapeutics (ARQT), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Replimune Group compare to Arcus Biosciences?

Replimune Group (NASDAQ:REPL) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Replimune Group currently has a consensus target price of $8.13, suggesting a potential downside of 18.26%. Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 24.80%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Arcus Biosciences had 4 more articles in the media than Replimune Group. MarketBeat recorded 9 mentions for Arcus Biosciences and 5 mentions for Replimune Group. Arcus Biosciences' average media sentiment score of 1.15 beat Replimune Group's score of 0.88 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Arcus Biosciences	$247M	14.32	-$353M	-$3.18	N/A

Replimune Group has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Arcus Biosciences beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Organon & Co.?

Replimune Group (NASDAQ:REPL) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Replimune Group has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.52

In the previous week, Replimune Group had 1 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Replimune Group and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.09 beat Replimune Group's score of 0.88 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a net margin of 3.99% compared to Replimune Group's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Organon & Co.	3.99%	99.95%	6.22%

Replimune Group currently has a consensus price target of $8.13, indicating a potential downside of 18.26%. Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 15.59%. Given Organon & Co.'s higher possible upside, analysts plainly believe Organon & Co. is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Organon & Co. beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Alumis?

Replimune Group (NASDAQ:REPL) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Alumis has higher revenue and earnings than Replimune Group. Alumis is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Alumis	$24.05M	148.96	-$243.32M	-$1.98	N/A

92.5% of Replimune Group shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Replimune Group has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Alumis	-2,825.70%	-88.79%	-70.72%

In the previous week, Alumis had 1 more articles in the media than Replimune Group. MarketBeat recorded 6 mentions for Alumis and 5 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.88 beat Alumis' score of 0.44 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Replimune Group has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Alumis has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market.

Replimune Group presently has a consensus target price of $8.13, indicating a potential downside of 18.26%. Alumis has a consensus target price of $40.30, indicating a potential upside of 43.42%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Alumis beats Replimune Group on 11 of the 16 factors compared between the two stocks.

How does Replimune Group compare to Arcutis Biotherapeutics?

Replimune Group (NASDAQ:REPL) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Replimune Group has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Replimune Group has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Replimune Group. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 5 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.88 beat Arcutis Biotherapeutics' score of 0.68 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.5% of Replimune Group shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Replimune Group presently has a consensus price target of $8.13, suggesting a potential downside of 18.26%. Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 25.37%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arcutis Biotherapeutics has higher revenue and earnings than Replimune Group. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Arcutis Biotherapeutics	$376.07M	9.02	-$16.14M	-$0.03	N/A

Summary

Arcutis Biotherapeutics beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Gemini Therapeutics?

Replimune Group (NASDAQ:REPL) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

In the previous week, Replimune Group had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for Gemini Therapeutics. Replimune Group's average media sentiment score of 0.88 beat Gemini Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gemini Therapeutics' return on equity of -38.78% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Replimune Group has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Replimune Group presently has a consensus price target of $8.13, indicating a potential downside of 18.26%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 5.2% of Replimune Group shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Replimune Group beats Gemini Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$922.56M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-2.94	20.85	27.11	24.26
Price / Sales	N/A	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.95	8.49	10.73	6.29
Net Income	-$313.94M	$23.83M	$3.58B	$330.66M
7 Day Performance	-13.64%	-3.56%	-2.11%	-1.35%
1 Month Performance	11.94%	6.31%	3.27%	-0.64%
1 Year Performance	-11.88%	48.30%	26.32%	19.08%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.0406 of 5 stars	$9.94 -9.6%	$8.13 -18.3%	-9.4%	$922.56M	N/A	N/A	210	News Coverage Options Volume
RCUS Arcus Biosciences	3.891 of 5 stars	$28.39 -5.2%	$35.10 +23.6%	+200.8%	$3.57B	$247M	N/A	500	News Coverage Positive News Insider Trade Gap Down
OGN Organon & Co.	2.8541 of 5 stars	$13.50 +0.0%	$11.40 -15.5%	+35.9%	$3.54B	$6.22B	14.51	10,000	Positive News
ALMS Alumis	3.1192 of 5 stars	$27.74 -8.5%	$40.30 +45.3%	+698.3%	$3.54B	$24.05M	N/A	N/A
ARQT Arcutis Biotherapeutics	3.8875 of 5 stars	$27.44 -4.7%	$34.00 +23.9%	+80.7%	$3.43B	$376.07M	N/A	150	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. RCUS, OGN, ALMS, ARQT, and GMTX

How does Replimune Group compare to Arcus Biosciences?

Summary

How does Replimune Group compare to Organon & Co.?

Summary

How does Replimune Group compare to Alumis?

Summary

How does Replimune Group compare to Arcutis Biotherapeutics?

Summary

How does Replimune Group compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. RCUS, OGN, ALMS, ARQT, and GMTX

How does Replimune Group compare to Arcus Biosciences?

Do institutionals & insiders hold more shares of REPL or RCUS?

Do analysts recommend REPL or RCUS?

Does the media refer more to REPL or RCUS?

Which has better earnings and valuation, REPL or RCUS?

Which has more risk and volatility, REPL or RCUS?

Is REPL or RCUS more profitable?

Summary

How does Replimune Group compare to Organon & Co.?

Do insiders and institutionals believe in REPL or OGN?

Which has more risk & volatility, REPL or OGN?

Which has higher valuation & earnings, REPL or OGN?

Does the media prefer REPL or OGN?

Is REPL or OGN more profitable?

Do analysts prefer REPL or OGN?

Summary

How does Replimune Group compare to Alumis?

Which has stronger valuation and earnings, REPL or ALMS?

Do institutionals & insiders believe in REPL or ALMS?

Is REPL or ALMS more profitable?

Does the media prefer REPL or ALMS?

Which has more risk and volatility, REPL or ALMS?

Do analysts prefer REPL or ALMS?

Summary

How does Replimune Group compare to Arcutis Biotherapeutics?

Is REPL or ARQT more profitable?

Which has more risk & volatility, REPL or ARQT?

Does the media refer more to REPL or ARQT?

Do institutionals and insiders hold more shares of REPL or ARQT?

Do analysts recommend REPL or ARQT?

Which has better valuation and earnings, REPL or ARQT?

Summary

How does Replimune Group compare to Gemini Therapeutics?

Does the media refer more to REPL or GMTX?

Is REPL or GMTX more profitable?

Which has better earnings and valuation, REPL or GMTX?

Which has more risk & volatility, REPL or GMTX?

Do analysts prefer REPL or GMTX?

Do insiders and institutionals believe in REPL or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools